Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $55000.0.

  • OptimizeRx's Change in Account Payables rose 12444.44% to $55000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$718000.0, marking a year-over-year decrease of 118787.88%. This contributed to the annual value of -$72000.0 for FY2024, which is 9454.55% up from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Change in Account Payables is $55000.0, which was up 12444.44% from -$1.4 million recorded in Q2 2025.
  • OptimizeRx's 5-year Change in Account Payables high stood at $1.3 million for Q2 2024, and its period low was -$1.4 million during Q2 2025.
  • In the last 5 years, OptimizeRx's Change in Account Payables had a median value of -$118971.0 in 2021 and averaged -$30487.9.
  • Per our database at Business Quant, OptimizeRx's Change in Account Payables soared by 107464.22% in 2022 and then crashed by 419346.93% in 2023.
  • Over the past 5 years, OptimizeRx's Change in Account Payables (Quarter) stood at -$164837.0 in 2021, then surged by 433.27% to $549354.0 in 2022, then plummeted by 183.92% to -$461000.0 in 2023, then decreased by 29.93% to -$599000.0 in 2024, then surged by 109.18% to $55000.0 in 2025.
  • Its last three reported values are $55000.0 in Q3 2025, -$1.4 million for Q2 2025, and $1.2 million during Q1 2025.